Research Analysts’ Weekly Ratings Changes for Oscar Health (OSCR)

Several analysts have recently updated their ratings and price targets for Oscar Health (NYSE: OSCR):

• 8/13/2026 – Oscar Health had its price target raised by Wells Fargo & Company from $20.00 to $27.00. They now have an “equal weight” rating on the stock.
• 8/12/2026 – Oscar Health had its “mixed” rating reaffirmed by Wells Fargo & Company.
• 8/11/2026 – Oscar Health had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $30.00 price target on the stock.
• 8/11/2026 – Oscar Health was upgraded by Weiss Ratings from “sell (d+)” to “hold (c+)”.
• 8/7/2026 – Oscar Health was given a new $27.00 price target by Robert W. Baird.
• 8/7/2026 – Oscar Health had its price target raised by UBS Group AG from $20.00 to $26.00. They now have a “neutral” rating on the stock.
• 8/6/2026 – Oscar Health had its price target raised by Barclays PLC from $35.00 to $39.00. They now have an “overweight” rating on the stock.
• 7/28/2026 – Oscar Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $36.00 price target on the stock.
• 7/10/2026 – Oscar Health was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 7/6/2026 – Oscar Health was upgraded by Zacks Research from “hold” to “strong-buy”.

Insider Activity

In other news, CEO Mark T. Bertolini sold 624,244 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $28.48, for a total value of $17,778,469.12. Following the completion of the sale, the chief executive officer owned 7,751,570 shares in the company, valued at $220,764,713.60. This represents a 7.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mario Schlosser sold 880,000 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $29.38, for a total transaction of $25,854,400.00. Following the completion of the sale, the director directly owned 480,866 shares of the company’s stock, valued at $14,127,843.08. The trade was a 64.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,241,556 shares of company stock worth $124,280,299 over the last 90 days. 22.64% of the stock is currently owned by corporate insiders.

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.